Kill Switch for CRISPR Could Make Gene Editing Safer - Scientific American
Untangling the CRISPR cancer scare
Development of a CRISPR/Cas9-based therapy for Hutchinson–Gilford progeria syndrome | Request PDF
A new research revealed that the CRISPR–Cas9 genome editing technique may increase cancer risk - Biotech Advisers
First Trial of CRISPR-Edited T cells in Lung Cancer: Trends in Molecular Medicine
PDF) The CRISPR tool kit for genome editing and beyond
CRISPR: gene editing is just the beginning : Nature News & Comment
:no_upscale()/cdn.vox-cdn.com/uploads/chorus_image/image/60457727/CRISPR_LEAD.0.jpg "CRISPR, one of the biggest science stories of the decade, explained - Vox")
CRISPR, one of the biggest science stories of the decade, explained - Vox
Developing CRISPR/CAS9 technologies for research and medicine - MedCrave online
First CRISPR editing trial results assuage safety concerns
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects | Signal Transduction and Targeted Therapy
A CRISPR Approach to Treating Sickle Cell – NIH Director's Blog
New CRISPR genome-editing system can target disease-causing genetic variations – Harvard Gazette
Single-dose CRISPR-Cas9 therapy extends lifespan of mice with Hutchinson-Gilford progeria syndrome. - Nat. Med. - X-MOL
Precision CRISPR system averts hearing loss in mice - Boston Children's Discoveries
Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy | Nature Medicine
Nature Medicine》基因编辑工具增加致癌隐患- 生物通
CRISPR, the disruptor : Nature News & Comment
Focus on CRISPR tools and therapies | Nature Biotechnology
CRISPR-Cas 9 corrects genetic defects in mice
CRISPR/Cas9 – An evolving biological tool kit for cancer biology and oncology | npj Precision Oncology
The next generation of CRISPR–Cas technologies and applications | Nature Reviews Molecular Cell Biology
CRISPR, the disruptor : Nature News & Comment
Nature Medicine - About the cover: Using CRISPR-Cas9–based genome editing technology, Sato and colleagues (featured on p 256 of this month's issue) introduce various combinations of mutations associated with human intestinal tumors
The kill-switch for CRISPR that could make gene-editing safer
